$CDLX

Gupta Amit sold $54K of CDLX

Gupta Amit (Chief Executive Officer) sold 13,461 shares of Cardlytics, Inc. (CDLX) at an average of $4.00 ($3.97–$4.03) across 2 trades over 2026-08-17 to 2026-08-18.

Original reporting
SEC EDGAR · Gupta Amit
Published Aug 18, 2026, 9:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CDLX
Neutral
high confidence
Mentioned
$CDLX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDLXNeutralLow
01

Why it matters

The disclosure provides a new datapoint on insider selling activity, but it does not include any new company performance, guidance, or deal information.

02

Market read

Traders may monitor for follow-on insider activity or corroborating company news, but this filing alone is unlikely to drive a major repricing.

03

What to watch

The filing does not state motivations, tax needs, or whether sales were planned; without follow-on insider buys or company news, trading impact is likely muted.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-18 after-hours

Background

The article reports an SEC Form 4 insider transaction by Cardlytics CEO Amit Gupta.

Company-level read

Ticker impact

$CDLXNeutralHigh confidence
Context

Cardlytics CEO Amit Gupta sold 13,461 shares in open-market trades at about $3.97 to $4.03, per a fresh SEC Form 4 filing.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless paired with other disclosures.

Evidence & confidence

The article is a primary-source Form 4 showing an open-market sale by the CEO, with no guidance, financial results, or regulatory/contract developments included.

Market effects

No clear sector read-through from a single insider open-market sale without additional context.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine liquidity events, especially without a 10b5-1 plan disclosed here, so the signal may be overstated.

Key entities

  • Cardlytics, Inc.

    Subject of the Form 4 insider transaction; CEO Amit Gupta sold shares in open-market trades.

  • Amit Gupta

    Cardlytics CEO and director who executed the reported sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDLXMedAI 8/10

Cardlytics (CDLX) Q2 2026 Earnings Call Transcript

Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$CDLXMed

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million